Therapeutic Options for the Treatment of Darier’s Disease: A Comprehensive Review of the Literature

Nardin Hanna¹, Megan Lam², Patrick Fleming³, and Charles W. Lynde³,⁴

Abstract
Darier’s disease (also known as keratosis follicularis or dyskeratosis follicularis) is an autosomal dominant inherited disorder which manifests as hyperkeratotic greasy papules in the first or second decade of life. Aside from symptom management and behavioral modifications to avoid triggers, there are currently no validated treatments for Darier’s disease (DD). However, a variety of treatments have been proposed in the literature including retinoids, steroids, vitamin D analogs, photodynamic therapy, and surgical excision. The purpose of this review article is to identify therapeutic options for treating DD and to outline the evidence underlying these interventions. A search was conducted in Medline for English language articles from inception to July 4, 2020. Our search identified a total of 474 nonduplicate studies, which were screened by title and abstract. Of these, 155 full text articles were screened against inclusion/exclusion criteria, and 113 studies were included in our review. We identified Grade B evidence for the following treatments of DD: oral acitretin, oral isotretinoin, systemic Vitamin A, topical tretinoin, topical isotretinoin, topical adapalene gel, topical 5-flourouracil, topical calciptriol and tacalcitol (with sunscreen), grenz ray radiation, and x-ray radiation. All other evidence for treatments of DD consisted of case reports or case series, which is considered grade C evidence. Considering the quality and quantity of evidence, clinicians may consider initiating a trial of select topical or oral retinoids first in patients with localized or generalized DD, respectively.

Keywords
Darier’s disease, treatment, genodermatosis

Introduction
Darier’s disease (also known as keratosis follicularis or dyskeratosis follicularis) is an autosomal dominant inherited disorder with variable expressivity.¹,² It occurs through mutations in the ATP2A2 gene, which encodes the sarcoplasmic reticulum ATPase type two (SERCA2) calcium pump.¹ This mutation manifests as hyperkeratotic greasy papules in the first or second decade of life.¹ The papules predominantly erupt on the seborrheic surfaces of the skin and are frequently accompanied by scaling and scabbing.³ On histology, Darier’s disease (DD) can be characterized by its distinctive features which include: acantholysis resulting in the formation of suprabasal clefts, and dyskeratosis involving corps ronds and grains.³ The prevalence of DD is estimated to be between one in 30,000, and one in 100,000.¹

There are currently no validated treatments for DD, with avoidance of triggers and symptom management being the mainstay.³ However, a variety of treatments have been proposed in the literature including retinoids, steroids, vitamin D analogs, photodynamic therapy and surgical excision.³ As such, identifying a targeted treatment for DD is a primary concern and was listed as a priority translational dermatology research question by over 70% of participants in the UK eDelphi study group.⁴ The purpose of this review article is to identify the therapeutic options for treating DD and to outline the evidence underlying these interventions. Identifying potential treatments and grading the evidence underlying these therapies can help create a therapeutic algorithm for treating DD patients. In addition, a review of effective treatments can offer potential treatment options for recalcitrant cases of the disease. Finally, this review may also highlight encouraging avenues for future research trials of interventions for DD.
Materials and Methods

The study was performed according to the Preferred Reporting Items for Systematic Reviews and Meta-analyses (PRISMA) guidelines, and registered in PROSPERO (International Prospective Register of Systematic Reviews, registration number CRD42020205964). A search was conducted in Medline for English language articles from database inception to July 4, 2020. The search strategy consisted of keywords and subject headings relating to the following two concepts combined with Boolean operators: Darier’s disease, and treatments. All search results were uploaded into Covidence Software for independent title/abstract and full-text screening by two reviewers (N.H. and M.L.). Articles were included if they provided data on treatments of DD and their outcome. Treatments were defined as interventions which had any positive effect in improving DD. We excluded articles which investigated the symptomatic treatment of patients with DD or which provided information on the use of etretinate in the treatment for DD, as this drug has been discontinued in North America. We also excluded review articles, conference abstracts and studies which were not available in the English language or studies for which the full text was not available. Disagreements were resolved through discussion between the reviewers.

Quality Assessment

We used a modified Newcastle-Ottawa Scale to assess the quality of included case reports, case series, and uncontrolled clinical trials or non-comparative cohort studies. We used the Cochrane Risk Of Bias In Non-Randomized Studies of Interventions (ROBINS-I) tool to assess the quality of controlled non-randomized trials. Two reviewers (N.H. and M.L.) assessed the quality of each included study. Disagreements were resolved through discussion between the reviewers.

Data Extraction and Synthesis

Data extraction was performed by the consensus of two independent reviewers (N.H. and O.S.) using a standard abstraction form including information about author, year of publication, study type, therapeutic modality used, regimen, duration of treatment, special indications, associated side effects or adverse events, and outcome of treatment. A series of evidence tables containing the extracted information were created. Evidence will be graded according to the Levels of Evidence to classify the quality of evidence support each intervention as follows: grade A, systematic reviews and meta-analysis or randomized control trials with consistent findings; grade B, systematic reviews/meta-analysis of lower-quality studies or studies with inconsistent findings, lower-quality clinical trials, cohort studies and case-control studies; Grade C, consensus guidelines, usual practice, expert opinion, case series and case reports. Grade A, B, and C quality of evidence will correspond to Grade one recommendation (strong recommendation; high-quality evidence), two A recommendation (weak recommendation; limited quality, patient-oriented evidence), and two B recommendation (weak recommendation; low-quality evidence) strength of recommendation, respectively.

Results

Our search identified a total of 474 nonduplicate studies, which were screened by title and abstract. Of these, 155 full text articles were screened against inclusion/exclusion criteria, and 113 studies were included in our review (Supplemental Figure 1). Risk of bias assessments for included studies can be found in Supplemental Tables 1 and 2. Therapies used for the treatment of DD can be subdivided into four categories: oral retinoids, other oral therapies, topical, and procedural (Supplemental Tables 3-6). Combination therapies reported in the literature for the treatment of DD are listed in Supplemental Table 3.

Systemic Therapies

Oral retinoids. We identified Grade C evidence for the use of oral retinoids as a treatment for DD when they were evaluated aggregately, likely through their antiproliferative effects on keratinocytes. In two included cohort studies with a total of 118 patients, 108 patients identified a benefit, however, significant side effects were reported in the majority of patients with this therapy, resulting in discontinuation by a significant number. Of note, oral retinoids used in the included studies include or may include etretinate and as such, results may not reflect the true efficacy of oral retinoids available in the United States and Canada at this moment.

Acitretin. There was Grade B evidence for the use of the oral retinoid, acitretin in improving DD. In two clinical trials evaluating the use of acitretin in 14 patients, all patients experienced improvement, with one study reporting significant improvement or complete clearance in four of five patients. There were significant side effects reported with the use of acitretin including: aridity cheilitis, increasing fragility of skin, dry mouth and skin, anorexia, pruritus, dry eye, hyperorexia, hearing handicap, brittle nail in one finger, acral hemorrhagic lesions, and mild elevation of serum triglyceride levels. Additionally, long-term treatment with acitretin may be necessary, as reoccurrence of DD has been noted in patients who terminate treatment.

Isotretinoin. There was also Grade B evidence for the use of the oral retinoid, isotretinoin in treating DD. In trial by Dicken et al., 98 of 104 patients with DD who used isotretinoin experienced improvement of their symptoms after
16 weeks of treatment. Patients whose disease persisted after this first round of therapy, received further treatment rounds, with similarly high rates of success. Three other trials with a cumulative 17 patients reported moderate to significant clearance in 14 patients, and mild improvement in 3 patients. Significant side effects reported with the use of oral isotretinoin including: epistaxis, cheilitis, xerosis, skeletal hyperostosis (after 6 to 12 months of use), conjunctivitis, facial dermatitis, rhinitis sicca with nosebleed, skin fragility, itching, headache, appetite changes, fingertip peeling, inflammation of the urethral meatus, hair thinning, dryness of mouth (with feeling of thirst), allergic reaction, and elevated AST, ALT, ALP, and ESR. In addition, termination of oral isotretinoin has resulted in relapse of DD. 

**Alitretinoin.** There were several case reports which (Grade C) reported on the benefits of alitretinoin, another oral retinoid. All patients using oral alitretinoin were reported to experience moderate to significant improvement of their DD. The side effects of alitretinoin include mild eye dryness, moderate reversible hair loss, headache, elevated total cholesterol, and low-density lipoprotein levels. Most notably, alitretinoin was used in women of child-bearing age, due to its shorter half-life, and correspondingly lower risk of teratogenicity when compared to other oral retinoids. However, similar to other oral retinoids, DD has been reported to relapse after discontinuation or decreased frequency of this treatment, and as a result, continuous treatment may be required.

**Vitamin A Analogs.** A variety of other systemic Vitamin A medications have been reported to treat DD including: Vitamin A, Vitamin A acid (tretinoin), and Vitamin A palmitate. The active metabolite of Vitamin A medications is retinoic acid, which similar to other retinoids, regulates hyperproliferation of keratinocytes. Our literature search identified Grade B evidence reporting partial to significant clinical improvement in patients receiving systemic Vitamin A. In a trial of seven patients receiving vitamin A, six experienced significant clinical improvement of their DD, while one patient experienced no clinical response. However, side effects of mild desquamation, pruritis, dry/scaling lips, dry nose, dry skin, headaches, sleepiness, and drowsiness were experienced by patients on this therapy. There was also evidence of partial relapse of DD after completing treatment. The use of oral Vitamin A Acid (tretinoin) was reported by one case series consisting of 8 patients (Grade C). All patients were able to control their DD using tretinoin, however side effects of cheilitis, rhinitis sicca, and skin cleavage, were observed. Additionally, relapses of DD was reported with the discontinuation of this medication. Finally, there was one case report describing the use of Vitamin A palmitate in the treatment of DD (Grade C). The patient experienced significant clinical improvement which persisted with the use of maintenance therapy, without any reported side effects.

**Systemic Immunosuppressants.** There was Grade C evidence for the use of methylprednisone, immunoglobulin, and cyclosporine as treatments for DD. These medications inhibit the inflammatory cycle, which may have a role in the exacerbation of DD. Two case reports investigated the use of methylprednisone and intravenous immunoglobulin and reported complete remission and significant improvement of DD, respectively. There were also three case reports with a total of four patients which described the benefits of cyclosporine in treating DD. Patients using cyclosporine reported adverse events (significant hypertension and acute renal failure) after starting the medication, and as a result, treatment was terminated. Similar to other treatments, it was also reported that DD may relapse after discontinuation of cyclosporine.

**Oral Magnesium.** There was one case report of oral magnesium used to successfully treat DD, without evidence of relapse for 1 month after treatment (Grade C). Due to the role of magnesium in inhibiting calcium efflux from cells, it may benefit patients with SERCA2 dysfunction (as in DD). However, as reported in the article, it is difficult to ascertain whether oral magnesium can treat DD or whether positive results are due to the clinical course of DD, which may often undergo remission spontaneously.

**Systemic Penicillamine.** The proposed mechanism of action of penicillamine involves its role in chelating copper used in the disulphide bonds of keratin, thereby decreasing keratinocyte proliferation. There was some evidence to support a trial of penicillamine as a treatment for DD, although it was poor and inconsistent (Grade C). In a case series of six patients receiving this medication, three patients experienced moderate to significant improvement of their DD, while three patients experienced only minimal or negligible improvement of their DD. Urticaria and eczema was also reported as a side effect of this treatment regimen in three of the six patients. Relapse of DD was also reported in every patient after discontinuation of penicillamine, suggesting that a long-term regimen or multiple treatment courses may be required.

**Systemic Antibiotics.** Although antibiotics are commonly used by patients with DD to treat superimposed cutaneous infections, we identified multiple case reports which investigated the use of doxycycline for the clearance of DD (Grade C). Doxycycline belongs to the class of tetracyclines which can suppress inflammation, epidermal proliferation, collagenase activity and infectious exacerbations, all of
which are mechanisms of DD. In the two patients treated with doxycycline, there was significant clinical improvement to complete remission of DD, which persisted for 3 months with maintenance therapy at the time of the report.

**Oral Contraceptives.** There have been multiple reports of exacerbations of DD associated with menstruation or pregnancy. Correspondingly, we found Grade C evidence of the use of estrogen as a treatment for DD in female patients experiencing flares of their skin disease when menstruating. Oostenhink et al. reported moderate clinical improvement with the use of Microgynon 50 (combination estrogen/progesterone pill) in one patient who experienced flares of her DD during menstruation.

**Topical Therapies**

**Topical Tretinoin.** Although the use of tretinoin (also known as all-trans-retinoic acid, retinoic acid or vitamin A acid) was the most frequently reported topical treatment for DD, the evidence for its efficacy was contradictory and of limited quality (Grade C). In Goh’s retrospective study of eight patients treated with topical retinoic acid, only two experienced mild benefit from this treatment. In one controlled trial of one patient with DD, areas treated with topical all-trans-retinoic acid were moderately improved, meanwhile placebo-treated areas were unchanged. In 12 alternate cases, however, therapy with tretinoin resulted in partial to complete remission of DD. Among patients, side effects of mild itching and tenderness, inflammation and desquamation were reported. Therapy with all-trans-retinoic acid was ultimately discontinued in two patients in Goh’s study, and the single patient in the control trial due to side effects of severe irritation, erythema and burning. Burge et al’s retrospective non-comparative cohort study of 163 patients with DD, it was reported that all patients who had been prescribed topical retinoic acid eventually discontinued treatment as it had a tendency to irritate skin. There was also evidence of relapse after discontinuation of treatment with topical tretinoin.

**Topical Isotretinoin.** Topical isotretinoin (also known as 13-cis-retinoic acid) was also identified as a treatment for DD in the literature, with variable effects on patients ranging from no response to complete remission of involved skin (Grade B evidence). In one trial of topical isotretinoin used to treat patients with DD, six of twelve patients achieved partial or complete remission of their DD. However, when visual analog scale ratings were compared before and after 3 months of treatment, there was no significant difference between the two ratings (mean difference 12.2 mm, SD = 31.4, P = .279). There were also several side effects reported with the use of topical isotretinoin in the literature. These include mild-severe burning, erythema, irritation, itching and tenderness.

**Topical Adapalene.** Adapalene was another retinoid identified in our search which was able to provide moderate to significant clinical improvement of DD (Grade B evidence). There were no notable side effects noticed on this treatment, however reoccurrence was reported after treatment was stopped.

**Topical Tazarotene.** In two case reports identified in our search, Tazarotene (a topical retinoid) resulted in complete remission of DD (Grade B). There were no notable side effects or reoccurrence reported for up to 24 months after remission.

**Topical Synthetic Vitamin D Analogs.** Vitamin D encourages differentiation and inhibits proliferation of epidermal keratinocytes, making it a potential therapeutic agent for DD. Correspondingly, there was grade B evidence supporting the efficacy of Vitamin D analogs Calcipotriol and Tacalcitol as treatments for DD in the literature. In a randomized right/left control trial of eleven DD patients, Calcipotriol resulted in worsening DD and lesional-perilesional skin irritation in eight patients (with seven patients out of the twelve dropping out due to adverse events), mild improvement in two patients, and moderate improvement in one patient. On the placebo side, however, only five of eleven patients experienced worsening DD, while two experienced moderate improvement and four experienced no changes. Alternately, Tacalcitol (used with sunscreen) was not found to have any notable side effects, however outcomes were variable, ranging from negligible response to significant clinical improvement of DD lesions.

**Topical Fluocinonide.** There was Grade C evidence for the use of Fluocinonide, a corticosteroid, as a treatment for DD in the literature. The use of topical Fluocinonide was evaluated in one case report and resulted in moderate to significant clinical improvement of DD in one patient.

**Topical Calcineurin Inhibitors.** As their name suggests, calcineurin inhibitors bind calcineurin, diminish T-cell proliferation, thereby inhibiting inflammation involved in symptomatic DD. Two types of topical calcineurin inhibitors were identified as treatments of DD in the literature: tacrolimus and pimecrolimus. Tacrolimus was described in one case report and resulted in the complete remission of DD lesions in one patient (Grade C evidence). With the use of maintenance therapy, this remission lasted for at least 12 months of follow-up. Pimecrolimus also resulted in the complete remission of DD lesions in one patient without any notable side effects (Grade C evidence).
**Topical Non-steroidal Anti-inflammatories.** The use of diclofenac sodium gel for treatment of DD was described in multiple reports in the literature (Grade C evidence).78-80 The proposed mechanism of action for this treatment is through COX-2 inhibition, which has the effect of upregulating production of the SERCA2 protein.78 Patients using this treatment experienced moderate to significant clinical improvement of their DD lesions, without any notable side effects. However, there was evidence of relapse after discontinuation of diclofenac sodium treatment.79

**Topical 5-Flourouracil.** There was Grade B evidence for the use of the chemotherapeutic agent, 5-flourouracil, for the treatment of DD.81-83 The mechanism of action of this therapy is inhibition of DNA synthesis, which decreases the hyperproliferation seen in DD.83 Variable success was reported with the use of this therapy ranging from no clinical response to complete remission81-83. In one non-controlled trial of four patients with DD, two patients experienced significant improvement of their DD, as well as symptomatic relief of symptoms including itching and burning.83 However, in the two patients who experienced treatment response, post-inflammatory hyperpigmentation was reported.83 Remission periods of two to six months were reported with the use of 5-flourouracil, with evidence of relapse in some patients.82,83

**Procedural Therapies**

**Surgical Excision and Dermabrasion.** Surgical excision was used to treat DD in several case reports with outcomes ranging from significant clinical improvement to complete remission (Grade C evidence).11,84-90 In these cases, partial-thickness and full-thickness surgical excision was used to remove areas of involved skin (or nails) with reconstruction using rotation flaps or skin grafts, when necessary.11,84-90 In one case, bilateral reduction mammaplasty was also used to achieve significant improvement of inframammary DD.89 Reported complications with surgical excision of DD include necrosis and exudate from wound, necrosis of the nipple-areolar complex (in the case of mammaplasty), wound dehiscence, infection, scar formation and hypopigmentation.84,86,87,89 Remission was maintained in some reports for as long as 3 years in skin excisions and 7 years in nail excisions.11,90 However, there was also evidence of relapse of DD in areas where surgical excision was less deep.85,90

There was Grade C evidence for use of dermabrasion for the treatment of DD.91 Patients experienced remission of at least 75% of the skin which was treated with dermabrasion for at least two and a half years.91 Similar to other studies, surgical intervention was successful when the papillary dermis was treated in addition to the superficial epidermal layers.91

**Lasers.** Lasers are believed to have their effect by destroying the superficial layer of skin (up to papillary dermis), and the eccrine glands, which have a role in exacerbating DD.92,93 The use of a carbon dioxide laser to treat DD was reported in several patients and resulted in outcomes ranging from moderate clinical improvement to complete remission (Grade C evidence).94-98 Side effects of this therapy included: irritation, edema, and erythema (may be transient or prolonged).94,96,97 Although remission durations of up to 9 years were reported after carbon dioxide laser therapy, reoccurrence of DD lesions was noted in multiple patients (although it was less severe).95,96,98

Erbium-doped yttrium and Erbium-doped fiber laser treatment was reported by Grade C evidence.99,100 Outcomes of patients treated with this therapy ranged from experiencing significant clinical improvement of their DD lesions to complete remission, with remissions lasting up to eighteen months at time of reporting.99,100 There were several side effects reported, however, including hypopigmentation (atrophic hypopigmented spots), pain, and transient erythema and edema.99,100

Flashlamp-pumped pulsed-dye lasers were reported on multiple occasions as significant potential in treating DD (Grade C evidence).101,102 In one case series of eight patients who received therapy with flashlamp-pumped pulsed-dye laser, all patients experienced significant clinical improvement or complete remission of their DD 3 months after treatment, with remission lasting up to 18 months in six patients.98 Side effects reported with this treatment include: purpura with mild crusting, and flare of herpes-simplex virus infection (occurred in two of eight patients in case series).101,102 There was also one case of DD treated with near-infrared 1450 nm wavelength diode laser, which resulted in complete remission of DD (Grade C).95 Remission was reported for 3 years at the time of report, without any notable side effects.95

**Radiation.** Although the exact mechanism of action is unknown, a variety of radiation techniques have been trialed with varying success in treating DD including Grenz Ray, electron beam radiation, conventional x-rays, and radiotherapy.103 Grenz ray radiation was compared with conventional x-ray and no radiation therapy in a single patient controlled trial (Grade B evidence). Outcomes were not significantly different after treatment completion, with improvement in all treatment areas.104 As such, it is difficult to ascertain whether improvement of DD can be attributed to these radiation therapies, or whether improvement occurred due to the spontaneous trajectory of DD.104

There was Grade C evidence for the use of electron beam radiation therapy as a treatment for DD.103,105,106 Outcomes of significant clinical improvement to complete remission of DD were reported in patients who were treated with localized and total electron beam therapy.105,106 Side effects observed after localized electron beam therapy included temporary local dermatitis and moist desquamation, striae in treatment areas, and mild disease flare outside the treatment area.105 However, after total electron beam radiation, more severe side effects were observed including severe dermatitis, skin pain, nausea, and vomiting.105 Ulceration and sclerosis also developed in areas treated with electron beam radiation and persisted after the
treatment course was complete.\textsuperscript{106} These adverse events resulted in prolonged hospitalization of one patient and admission to the intensive care unit.\textsuperscript{105}

Alternately, photon radiation therapy was chosen to treat DD patients with thickened hyperkeratotic contours due to its ability to penetrate more deeply.\textsuperscript{106} Unlike electron beam radiation therapy, there were no significant side effects reported with the use of this treatment, except for temporary pain.\textsuperscript{106} Patients in this case series experienced moderate to significant improvement of their DD after one to two courses of photon radiation therapy (Grade C evidence).\textsuperscript{106}

There was Grade C evidence for the use of radiotherapy as a treatment for DD.\textsuperscript{107,108} In multiple case reports, patients who were treated with radiotherapy for a malignancy experienced complete remission of their DD, with only mild side effects of local dermatitis or temporary exacerbation of their DD lesions.\textsuperscript{107,108} However, it is important to consider that has also been evidence to suggest that radiotherapy may trigger the onset of DD.\textsuperscript{109}

**Photodynamic Therapy.** Photodynamic therapy uses UV radiation to cause reactive oxygen species formation and subsequently apoptosis in involved skin.\textsuperscript{110} There is varying evidence for the use of photodynamic therapy in the treatment of DD with some literature reporting complete remission, and others reporting only temporary clearing followed by exacerbation (Grade B).\textsuperscript{110-112} In some patients, remission was achieved for a duration of 7 months to 3 years at time of report.\textsuperscript{110

---

**Figure 1.** Recommended treatment algorithm for management of Darier’s disease. TBSA: Total Body Surface Area. *Grade 2A+ recommendation with smaller quantity of evidence.
**Discussion**

The following treatments for DD were identified as having the strongest quality of evidence: oral acitretin, oral isotretinoin, systemic Vitamin A, topical tretinoin, topical isotretinoin, topical adapalene gel, topical 5-flouracil, topical calciptriol and tacalcitol (with sunscreen), grenz ray, and x-ray. The evidence underlying each of these treatments was awarded a grade B which corresponds to a 2A grade of recommendation for each treatment (weak recommendation due to limited quality patient-oriented evidence). However, despite the similar quality of evidence scores, there were significantly more studies highlighting the use of oral acitretin and isotretinoin and topical tretinoin and isotretinoin as effective treatments for DD (although response was variable from negligible to complete remission). All other evidence for treatments of DD were in the form of case reports or case series, which are considered grade C evidence. Based on this data, a recommended algorithm was created for managing DD (Figure 1). This summary does not include data about effective combination treatments used for managing DD. In general, most combination treatments consisted of 2 single agents from the options presented in this review. One except was naltraxone which was reported exclusively in combination with magnesium and other oral retinoids. A summary of combination treatments for DD can be found in Supplemental Table 7.

One consideration when choosing a treatment for DD is the risk of relapse with these therapies. In almost all trialed interventions, relapse was reported in subjects after discontinuation. As such, intermittent courses of therapy or long-term maintenance dosing may be required to prevent the recurrence of this disease. However, there were no reports of relapse in patients trialed on oral magnesium, topical isotretinoin, topical tazarotene, topical calciptriol, topical ticalcalcitiol, erbium-doped yttrium radiation, grenz ray radiation, x-ray radiation, electron beam radiation, photon radiation, and radiotherapy. It is difficult to ascertain whether patients trialed on these therapies did not experience relapse at any point after treatment as time of follow-up was either not reported in many studies or was very short (1 month to 3 years). Long-term studies investigating the use of these interventions will be required to make recommendations on treatments providing the longest remission periods. As it stands the treatment with longest remission period which was recorded in the literature was through surgical excision which lasted up to 9 years in one patient at time of report.

**Limitations**

Our study had several limitations. First, most articles identified in our search were case reports or case series, which are limited by reporting bias. Due to the low prevalence of DD, clinical trials or cohort studies also had small sample sizes, which limits the power of the results. Future studies may consider high-powered trials of DD treatments with the goal of providing grade A evidence for treatments. Finally, there is no objective measure of DD control, and as such, most studies used subjective clinician ratings of response to treatments. This may have resulted in inter-observer disparities when evaluating response.

**Conclusion**

DD is an autosomal dominant genodermatosis which presents with hyperkeratotic papules that may be accompanied by scaling and crusting. A variety of treatments which have been used to treat this disease in the literature, although the quality of the evidence remains poor (consisting predominantly of case reports and non-experimental studies). The best quality and quantity of evidence exists for the use of select oral and topical retinoids. Emerging evidence suggest interventional treatments such as surgical excision, lasers, and radiotherapy, may be effective in the treatment of DD. Further studies on efficacy and safety in comparative randomized trials would be important.

**Declaration of Conflicting Interests**

PF has received honorarium and/or consulting and/or advisory boards and/or speaking fees for AbbVie, Altius, Amgen, Aralez, Bausch Health, Cipher, Galderma, Eli Lilly, L’Oreal, UCB, Janssen, Medexus Pharmaceuticals, Novartis, Pfizer, and Sanofi-Genzyme. CL has been a speaker, principal investigator, and/or consultant to: AbbVie, AbbVie, Allergan, Amgen, Aralez, Arcutis, Astellas, Basilea, Bausch Health, Bayer, Boehringer Ingelheim, BMS, Celgene, Cipher, Eli Lilly, EMD Serono, Fresenius Kabi, Galderma, Glaxo Smith Kline, H3 Pharmaceuticals, Innovaderm, Janssen, Johnson & Johnson, Kyowa, La Roche Posay, L’Oreal, Leo Pharma, Merck, Medexus, Mylan, Novartis, Ortho Biotech, Pedipharma, Pfizer, Roche, Sanofi Aventis, Sanofi Genzyme, Stiefel, TEVA, Tribute, Valeant, Viatris, Volo Health, Westwood Squibb, Wyeth. NH and ML have no conflicts of interest to declare.

**Funding**

The author(s) received no financial support for the research, authorship, and/or publication of this article.

**Supplemental Material**

Supplemental material for this article is available online.

**References**

1. Sehgal VN, Srivastava G, Ge S. Darien’s (Darier-White) disease/keratosis follicularis. *Int J Dermatol*. 2005;44(3):184-192. doi:10.1111/j.1365-4632.2004.02408.x
2. Cooper SM, Burge SM. Darien’s disease: epidemiology, pathophysiology, and management. *Am J Clin Dermatol*. 2003;4(2):97-105. doi:10.2165/00128071-200304020-00003
3. Takagi A, Kamijo M, Ikeda S. Darien disease. *J Dermatol*. 2016;43(3):275-279. doi:10.1111/1346-8138.13230
4. Healy E, Brown SJ, Langan SM, Nicholls SG, Shams K, Reynolds NJ. Identification of translational dermatology research
priorities in the U.K.: results of an electronic Delphi exercise. Br J Dermatol. 2015;173(5):1191-1198. doi:10.1111/bjd.14022
5. Moher D, Liberati A, Tetzlaff J, Altman DG, et al. Preferred reporting items for systematic reviews and meta-analyses: the PRISMA statement. PLoS Med. 2009;6(7):e1000097. doi:10.1371/journal.pmed.1000097
6. Murad MH, Sultan S, Haflar S, Bazerbachi F. Methodological quality and synthesis of case series and case reports. BMJ Evid Based Med. 2018;23(2):60-63. doi:10.1136/bmjebm-2017-110853
7. Robinson JK, Dellavalle RP, Bigby M, Callen JP. Systematic reviews: grading recommendations and evidence quality. Arch Dermatol. 2008;144(1):97-99. doi:10.1001/archdermatol.2007.28
8. Burge SM, Wilkinson JD. Darier-White disease: a review of the clinical features in 163 patients. J Am Acad Dermatol. 1992;27(1):40-50. doi:10.1016/0190-9622(92)70154-8
9. Vieira ML, de Paula Samorano L, da Matta Rivitti-Machado MC, de Oliveira ZNP. Darier disease: long-term treatment with systemic retinoids at a tertiary hospital. J Dtsch Dermatol Ges. 2020;18(6):628-630. doi:10.1111/ddg.14113
10. Zhang X-B, Luo Q, Li C-X, He Y-Q, Xu X. Clinical investigation of acitretin in children with severe inherited keratinization disorders in China. J Dermatolog Treat. 2008;19(4):221-228. doi:10.1080/09546630801955150
11. Sprowson AP, Jeffery SLA, Black MJM. Darier’s disease, an unusual problem and solution. J Hand Surg Am. 2004;29(3):293-295. doi:10.1016/j.jhsa.2003.12.005
12. Goh BK, Ang P, Goh CL. Darier’s disease in Singapore. Br J Dermatol. 2005;152(2):284-288. doi:10.1111/j.1365-2133.2004.06364.x
13. Itin PH, Happle R. Darier disease with paired segmental manifestation of either excessive or absent involvement: a further step in the concept of twin spotting. Dermatology. 2002;205(4):344-347. doi:10.1159/000066423
14. Parslew R, Verbov JL. Kaposi’s varicelliform eruption due to herpes simplex in Darier’s disease. Clin Exp Dermatol. 1994;19(5):428-429. doi:10.1111/j.1365-2230.1994.tb02703.x
15. Parlak M, Erdem T, Karakuzu A, Güleç AI, Akdeniz N. Darier’s disease seen with cutis verticis gyrata. Acta Derm Venereol. 2001;81(1):75. doi:10.1080/000155501750208380
16. Katta R, Reed J, Wolf JE. Cornifying Darier’s disease. Int J Dermatol. 2000;39(11):844-845. doi:10.1046/j.1365-4362.2000.00994.x
17. Borgogna C, Zavattaro E, Dell’Oste V, et al. No indications for HPV involvement in the hypertrophic skin lesions of a Darier disease case without ATP2A2 gene mutations. J Cutan Pathol. 2009;36(9):1005-1009. doi:10.1111/j.1600-0560.2009.01182.x
18. Zavattaro E, Celasco M, Delrosso G, et al. Acitretin-induced acral hemorrhagic lesions in Darier-White disease. Cutis. 2014;94(6):E1-5. http://www.ncbi.nlm.nih.gov/pubmed/25566576
19. Flores-Terry MÁ, Garcia-Arpa M, Llamas-Velasco M, Mendoza-Chaparro C, Ramos-Rodriguez C, De Darier E. Acral Hemorrhagic Darier Disease. 108; 2017.
20. Liang J, Chen P, Chen H, et al. Long-term safety and efficacy of continuous acitretin monotherapy for three children with different severe hyperkeratotic disorders in China. J Dermatol. 2018;45(8):1003-1008. doi:10.1111/1346-8138.14462
21. Blanchet-Bardon C, Nazzaro V, Rognin C, Geiger JM, Puissant A. Acitretin in the treatment of severe disorders of keratinization. Results of an open study. J Am Acad Dermatol. 1991;24(6 Pt 1):982-986. doi:10.1016/0190-9622(91)70158-x
22. Magdaleno-Tapia J, Valenzuela-Oñate C, Martinez-Domenech Á, Garcia-Legaz-Martinez M, Sánchez-Carazo JL, Alegre-de Miquel V. A purigrinous eruption on the back, worsening in the summer. Clin Exp Dermatol. 2019;44(7):794-796. doi:10.1111/ced.13865
23. van Dooren-Greebe RJ, van de Kerkhof PC, Happle R. Acitretin monotherapy in Darier’s disease. Br J Dermatol. 1989;121(3):375-379. doi:10.1111/j.1365-2133.1989.tb01432.x
24. Peck GL, Yoder FW, Olsen TG, Pandya MD, Butkus D. Treatment of darier’s disease, lamellar ichthyosis, pityriasis rubra pilaris, cystic acne, and basal cell carcinoma with oral 13-cis-retinoic acid. Dermatology. 1978;157(1):11-12. doi:10.1159/000250878
25. Peck GL, Yoder FW. Treatment of lamellar ichthyosis and other keratinising dermatoses with an oral synthetic retinoid. Lancet. 1976;2(7996):1172-1174. doi:10.1016/S0140-6736(76)91685-8
26. Archer CB, Elias PM, Lowe NJ, Griffiths WA. Extensive spinal hyperostosis in a patient receiving isotretinoin—progression after 4 years of etretinate therapy. Clin Exp Dermatol. 1989;14(4):319-321. doi:10.1111/j.1365-2230.1989.tb01993.x
27. Ellis CN, Madison KC, Penne DR, Martel W, Voorhees JJ. Isotretinoin therapy is associated with early skeletal radiographic changes. J Am Acad Dermatol. 1984;10(6):1024-1029. doi:10.1016/S0190-9622(84)80329-1
28. Dicken CH, Bauer EA, Hazen PG, et al. Isotretinoin treatment of Darier’s disease. J Am Acad Dermatol. 1982;6(4):721-726. doi:10.1016/0190-9622(82)80052-2
29. Farb RM, Lazarus GS, Chiaromanti A, Goldsmith LA, Gilgor RS, Balakrishnan CV. The effect of 13-cis retinoic acid on epidermal lysosomal hydrolyase activity in Darier’s disease and pityriasis rubra pilaris. J Invest Dermatol. 1980;75(2):133-135. doi:10.1111/j.1523-1747.ep1251639
30. Bhat RM, Ullal KR, Pinto AC, Sukumar D. Darier-White disease in siblings responding to isotretinoin. Indian Dermatol Online J. 2010;1(1):18. doi:10.4103/2229-5178.73252
31. Orihuela E, Tyring SK, Pow-Sang M, et al. Development of human papillomavirus type 16 associated squamous cell carcinoma of the scrotum in a patient with Darier’s disease treated with systemic isotretinoin. J Urol. 1995;153(6):1940-1943. doi:10.1016/S0022-5347(01)67363-4
32. Blackman HJ, Rodrigues MM, Peck GL. Corneal epithelial lesions in keratosis follicularis (Darier’s disease). Ophthalmo-lology. 1980;87(9):931-943. doi:10.1016/S0161-6420(80)35142-7

33. Hussain W, Coulson IH, Salman WD. Pityriasis amiantacea as the sole manifestation of Darier’s disease. Clin Exp Dermatol. 2009;34(4):554-556. doi:10.1111/j.1365-2230.2008.02929.x

34. Zamiri M, Munro CS. Successful treatment with oral alitretinoin in women of childbearing potential with Darier’s disease. Br J Dermatol. 2013;169(3):709-710. doi:10.1111/bjd.12348

35. Anuset D, Goutorbe C, Bernard P, Reguiai Z. Efficacy of oral alitretinoin in women of childbearing potential with Darier’s disease. J Am Acad Dermatol. 2014;71(2):e46-e48. doi:10.1016/j.jaad.2014.01.876

36. Letulé V, Herzinger T, Ruzicka T, Molin S. Treatment of Darier disease with oral alitretinoin. Clin Exp Dermatol. 2013;38(5):523-525. doi:10.1111/ced.12078

37. Shreberk-Hassidim R, Sheffer S, Horev L, Zlotogorski A, Ramot Y. Successful treatment of refractory Darier disease with alitretinoin with a follow up of over a year: a case report. Dermatol Ther. 2016;29(4):222-223. doi:10.1111/dth.12366

38. Stüttgen G, Ippen H, Mahrle G, Mahrle G. Oral vitamin A acid in treatment of dermatoses with pathologic keratinization. Int J Dermatol. 1977;16(6):500-502. doi:10.1111/1365-4362.1977.tb01863.x

39. Thomas JR, Cooke JP, Winkelmann RK. High-dose vitamin A therapy for Darier’s disease. Arch Dermatol. 1982;118(11):891-894. doi:10.1001/archderm.1982.016503009109

40. Sondhi M, Vashist S, Mahajan VK. Darier’s disease - Response to oral vitamin A: report of a case and brief review. Indian Dermatol Online J. 2020;11(1):72-78. doi:10.4103/idoj.I DOI_85.19

41. Ayres S. Darier’s disease: update on an effective new therapy. Arch Dermatol. 1983;119(9):710. doi:10.1001/archderm.1983.0165033002003

42. Burgoon CF, Graham JH, Urbach F, Musgnug R. Effect of vitamin A on epithelial cells of skin. The use of vitamin A in the treatment of diseases characterized by abnormal keratinization. Arch Dermatol. 1963;87(1):63-80. doi:10.1001/archderm.1963.01590130069012

43. Mei S, Amato L, Gallerani I, et al. A case of vesiculo-bullous Darier’s disease associated with bipolar psychiatric disorder. J Dermatol. 2000;27(10):673-676. doi:10.1111/j.1346-8138.2000.tb02252.x

44. Legrand A, Darrigade A-S, Taieb A, Milpied B, Seneschal J. Response to low-dose intravenous immunoglobulin in a case of recalcitrant Darier disease. JAAD Case Rep. 2020;6(3):189-191. doi:10.1016/j.jder.2020.01.007

45. Stewart LC, Yell J. Vulval Darier’s disease treated successfully with ciclosporin. J Obstet Gynaecol. 2008;28(1):108-109. doi:10.1080/01443610701844077

46. Shahidullah H, Humphreys F, Beveridge GW. Darier’s disease: severe eczematization successfully treated with ciclosporin. Br J Dermatol. 1994;131(5):713-716. doi:10.1111/j.1365-2133.1994.tb04990.x

47. Gupta AK, Ellis CN, Nickoloff BJ, et al. Oral ciclosporin in the treatment of inflammatory and noninflammatory dermatoses. A clinical and immunopathologic analysis. Arch Dermatol. 1990;126(3):339-350. doi:10.1001/archderm.1990.01670270071012

48. Yamamoto T, Aoyama Y. Role of pro-inflammatory cytokines in the pathophysiology of herpes simplex virus superinfection in Darier’s disease. J Dermatol. 2021;16097:1346-8138. doi:10.1111/1346-8138.16097

49. Dalakas MC. Mechanism of action of intravenous immunoglobulin and therapeutic considerations in the treatment of autoimmune neurologic diseases. Neurology. 1998;51(6 Suppl 5):S2-S8. doi:10.1212/WNL.51.6.S2

50. Sloka JS, Stefanelli M. The mechanism of action of methylprednisolone in the treatment of multiple sclerosis. Mult Scler. 2005;11(4):425-432. doi:10.1119/1352458505ms11900a

51. Oi-Yee Li H, Colantonio S, Kangsbergs N. Treatment of Darier’s disease with oral magnesium: a case report. SAGE Open Med Case Rep. 2018;6:2050313X1879507. doi:10.1177/2050313X187950701

52. Beer WE, Lyle WH. Penicillamine for the treatment of Darier’s disease and other disorders of keratin formation. Lancet. 1966;288(7477):1337-1340. doi:10.1016/S0140-6736(66)92084-8

53. Sfecci A, Orion C, Darrieux L, Tisseau L, Safa G. Extensive Darier disease successfully treated with doxycycline monotherapy. Case Rep Dermatol. 2015;7(3):311-315. doi:10.1159/000444167

54. Pettit C, Ulman CA, Spohn G, Kaffenberger J. A case of segmental Darier disease treated with doxycycline monotherapy. Dermatol Online J. 2018;24(3):13030/qt2827f6qq. https://europepmc.org/article/med/29634885

55. Le Saché-de-Feuilléhoux L, Raynaud E, Bouchardeau A, Fraitag S, Bodemer C. Familial benign chronic pemphigus and therapeutic considerations in the treatment of autoimmune neurologic diseases. Clin Exp Dermatol. 2018;42(3):370-373. doi:10.1111/ced.12266

56. Oostenbrink JH, Cohen EB, Steijlen PM, van de Kerkhof PC. Oral contraceptives in the treatment of Darier-White disease -a case report and review of the literature. Clin Exp Dermatol. 1996;21(6):442-444. doi:10.1111/j.1365-2230.1996.tb00152.x

57. Fulton JE, Gross PR, Cornelius CE, Kligman AM. Darier’s disease. treatment with topical vitamin A acid. Arch Dermatol. 1968;96(4):396-399. doi:10.1001/archderm.96.8.396

58. Heschbener EN. Zosteriform keratosis follicularis treated topically with tretinoin. Arch Dermatol. 1970;102(2):209-212. doi:10.1001/archderm.1970.04000080081106

59. Meziane M, Chraibi R, Kihel N, Hassam B, Senouci K. Linear Darier disease. Dermatol Online J. 2008;14(12):11. http://www.ncbi.nlm.nih.gov/pubmed/19265624
60. O’Malley MP. Localized Darier disease. Arch Dermatol. 1997;133(9):1134. doi:10.1001/archderm.1997.03890450

61. Dogan S, Karaduman A, Erkin G, Gokoz O. Effective treatment of linear Darier’s disease with topical retinoids: Case report and review of the literature. Acta Dermatovenerologica Croata. 2011;19(3):206-209.

62. Vender R, Vender R. Acral hemorrhagic Darier’s disease: a case report. J Cutan Med Surg. 2016;20(5):478-480. doi:10.1177/1203475416640993

63. De Panfilis G, Manara GC, Ferrari C, Tedeschi F, Allegre F. Darier’s keratosis follicularis: an ultrastructural study during and after topical treatment with retinoic acid alone or in combination with 5-fluorouracil. J Cutan Pathol. 1981;8(3):214-218. doi:10.1111/j.1600-0560.1981.tb01000.x

64. Steijlen PM, Happle R, Van Muijen GNP, Van De Kerkhof PCM. Topical treatment with 13-cis-retinoic acid improves darier’s disease and induces the expression of a unique keratin pattern. Dermatology. 1991;183(3):178-183. doi:10.1159/000247778

65. Burge SM, Buxton PK. Topical isotretinoin in Darier’s disease. Br J Dermatol. 1995;133(6):924-928. doi:10.1111/j.1365-2133.1995.tb06927.x

66. McKenna KE, Walsh MY, Burrows D. Treatment of unilateral Darier’s disease with topical isotretinoin. Clin Exp Dermatol. 1999;24(5):425-427. doi:10.1046/j.1365-2230.1999.00519.x

67. Steijlen PM, Reifschneider DO, Ramaekers FC, et al. Topical treatment of ichthyosis and Darier’s disease with 13-cis-retinoic acid. A clinical and immunohistochemical study. Arch Dermatol Res. 1993;285(4):221-226. doi:10.1007/BF00372013

68. Cianchini G, Colonna L, Camaioni D, Annessi G, Puddu P. Acral Darier’s disease successfully treated with adapalene gel. Acta Derm Venereol. 2001;81(1):57-58. doi:10.1080/000155501750208245

69. Abe M, Inoue C, Yokoyama Y, Ishikawa O. Successful treatment of Darier’s disease with adapalene gel. Pediatr Dermatol. 2011;28(2):197-198. doi:10.1111/j.1525-1470.2009.01077.x

70. CasalsM,CampoyA,AspioleaF,CarrascoMA,CampsA. Successful treatment of linear Darier’s disease with topical adapalene. J Eur Acad Dermatol Venereol. 2009;23(2):237-238. doi:10.1111/j.1468-3083.2008.02815.x

71. Oster-Schmidt C. The treatment of Darier’s disease with topical tazarotene. Br J Dermatol. 1999;141(3):603-604. doi:10.1046/j.1365-2133.1999.03089.x

72. Micali G, Nasca MR. Tazarotene gel in childhood Darier disease. Pediatr Dermatol. 1999;16(3):243-244. http://www.ncbi.nlm.nih.gov/pubmed/10383788

73. Kragballe K, Steijlen PM, Ibsen HH, et al. Efficacy, tolerability, and safety of calcipotriol ointment in disorders of keratinization. Results of a randomized, double-blind, vehicle-controlled, right/left comparative study. Arch Dermatol. 1995;131(5):556-560. doi:10.1001/archderm.1995.01690170

74. Abe M, Yasuda M, Yokoyama Y, Ishikawa O. Successful treatment of combination therapy with tacalcitol lotion associated with sunscreen for localized Darier’s disease. J Dermatol. 2010;37(8):718-721. doi:10.1111/j.1346-8138.2010.00910.x

75. Acute FHC, Disease ED. Keratosis follicularis): occurrence in an adult. Arch Dermatol. 1975;111(2):221-222. doi:10.1001/archderm.1975.01630140079009

76. Perez-Carmona L, Fleta-Asín B, Moreno-García-Del-Real C, Jaén-Olansolo P. Successful treatment of Darier’s disease with topical pimecrolimus. Eur J Dermatology. 2011;21(2):301-302. doi:10.1684/edj.2011.1309

77. Rubegni P, Poggiali S, Shano P, Risulo M, Fimiani M. A case of Darier’s disease successfully treated with topical tacrolimus. J Eur Acad Dermatol Venereol. 2006;20(1):84-87. doi:10.1111/j.1468-3083.2005.01352.x

78. Palacios-Álvarez I, Andrés-Ramos I, Silva MY, Simal G. Treatment of Darier’s disease with diclofenac sodium 3% gel. Dermatol Ther. 2017;30(3):e12478. doi:10.1111/dth.12478

79. Millán-Parrilla F, Rodrigo-Nicolás B, Molés-Poveda P, Armengot-Carbó M, Quecedo-Estebénez E, Gimeno-Carpio E. Improvement of Darier disease with diclofenac sodium 3% gel. J Am Acad Dermatol. 2014;70(4):e89-e90. doi:10.1016/j.jaad.2013.11.033

80. Santos-Alarcon S, Sanchis-Sanchez C, Mateu-Puchades A. Diclofenac sodium 3% gel for darier’s disease treatment. Dermatol Online J. 2016;22(4). http://www.ncbi.nlm.nih.gov/pubmed/27617470

81. Yoon TY, Kim JW, Kim MK. Successful treatment of Darier disease with topical 5-fluorouracil. Br J Dermatol. 2006;154(6):1210-1212. doi:10.1111/j.1365-2133.2006.07267.x

82. Knulst AC, De La Faille HB, Van Vloten WA. Topical 5-fluorouracil in the treatment of Darier’s disease. Br J Dermatol. 1995;133(3):463-466. doi:10.1111/j.1365-2133.1995.tb02679.x

83. Schmidt H, Oechsendorf FR, Wolter M, Geisslinger G, Ludwig RJ, Kaufmann R. Topical 5-fluorouracil in Darier disease. Br J Dermatol. 2008;158(6):1393-1396. doi:10.1111/j.1365-2133.2008.08557.x

84. Ji WB, Joung S-Y, Min B-W, Um JW. Surgical excision for non-familial hypertrophic Darier’s disease. J Plast Reconstr Aesthetic Surg. 2009;62(11):e442-e446. doi:10.1016/j.bjps.2008.06.060
88. Baran R. An effective surgical treatment for nail thickening in Darier’s disease. J Eur Acad Dermatol Venereol. 2005;19(6):689-691. doi:10.1111/j.1468-3083.2005.01263.x

89. Cohen PR. Darier disease: sustained improvement following reduction mammoplasty. Cutis. 2003;72(2):124-126. http://www.ncbi.nlm.nih.gov/pubmed/12953935

90. Dellon AL, Chretien PB, Peck GL. Successful treatment of Darier’s disease by partial-thickness removal of skin. Plast Reconstr Surg. 1977;59(6):823-830. doi:10.1097/00006534-197706000-00006

91. Zachariae H. Dermabrasion of Hailey-Hailey disease and Darier’s disease. J Am Acad Dermatol. 1992;27(1):136. doi:10.1016/S0190-9622(08)0032-8

92. Preissig J, Hamilton K, Markus R. Current laser resurfacing technologies: a review that Delves beneath the surface. Semin Plast Surg. 2012;26(3):109-116. doi:10.1055/s-0032-1329413

93. O’Brien KF, Fricke MA, Kent RA, DeKlotz CMC. Laser treatment of Darier disease: report of two cases and systematic review of the literature. J Lasers Med Sci. 2020;11(4):395-404. doi:10.34172/jlms.2020.63

94. Benmously R, Litaiem N, Hammami H, Badri T, Fenniche S. Laser ablation. Arch Dermatol. 1999;135(4):423-427. doi:10.1001/archderm.135.4.423

95. Brown VL, Kelly SE, Burge SM, Walker NPJ. Extensive reduction mammaplasty. Cutis. 1977;06000-00006

96. Krakowski AC, Nguyen TA, Eichenfield LF. Treatment of recalcitrant Darier disease successfully treated with laser ablation. Br J Dermatol. 2010;162(1):227-229. doi:10.1111/j.1365-2133.2009.09540.x

97. Raszewska-Famielec M, Dudra-Jastrzębska M, Borzęcki A, Chodorowska G. Darier-White disease treated with fractional CO2 laser. J Cosmet Laser Ther. 2015;17(2):77-79. doi:10.3109/14764712.2014.988728

98. Brown VL, Kelly SE, Burge SM, Walker NPJ. Extensive recalcitrant Darier disease successfully treated with laser ablation. Br J Dermatol. 2010;162(1):227-229. doi:10.1111/j.1365-2133.2009.09540.x

99. Bennously R, Litaïem N, Hammami H, Badri T, Fenniche S. Significant alleviation of Darier’s disease with fractional CO2 laser. Dermatol Ther. 2015;28(4):254-257. doi:10.1111/dth.12226

100. Krakowski AC, Nguyen TA, Eichenfield LF. Treatment of segmental keratosis follicularis (Darier disease) using ablative fractional laser resurfacing. Dermatol Surg. 2015;41(4):516-518. doi:10.1097/DSS.0000000000000315

101. McElroy JA, Mehregan DA, Roenigk RK. Carbon dioxide laser vaporization of recalcitrant symptomatic plaques of Hailey-Hailey disease and Darier’s disease. J Am Acad Dermatol. 1990;23(5 Pt 1):893-897. doi:10.1016/0190-9622(90)70311-5

102. Katz TM, Firoz BF, Goldberg LH, Friedman PM. Treatment of Darier’s disease using a 1,550-nm erbium-doped fiber laser. Dermatol Surg. 2010;36(1):142-146. doi:10.1111/j.1524-4725.2009.01369.x

103. Beier C, Kaufmann R. Efficacy of erubum: YAG laser ablation in Darier disease and Hailey-Hailey disease. Arch Dermatol. 1999;135(4):423-427. doi:10.1001/archderm.135.4.423

104. Cannarozzo G, Bonciani D, Sannino M, et al. Dye laser treatment for Darier disease: results of a case series. Photomed Laser Surg. 2016;34(7):305-307. doi:10.1089/pho.2015.4034

105. Roos S, Karsai S, Ockenfel H-M, Raulin C. Successful treatment of Darier disease with the flashlamp-pumped pulsed-dye laser. Arch Dermatol. 2008;144(8):1073-1075. doi:10.1001/archderm.144.8.1073

106. Rodriguez LM, Kazemi T, Cheng CE, et al. Focal multimodality radiation therapy: a promising treatment for recalcitrant Darier disease. Dermatol Ther. 2018;31(4):e12641. doi:10.1111/dth.12641

107. Cipollaro VA, Shaps R. The treatment of Darier’s disease. Int J Dermatol. 1979;18(7):580-583. doi:10.1111/j.1365-4362.1979.tb01977.x

108. Kittridge A, Wahlgren C, Fuhrer R, Zirwas M, Patton T. Treatment of recalcitrant Darier’s disease with electron beam therapy. Dermatol Ther. 2010;23(3):302-304. doi:10.1016/j.jdermt.2010.01327.x

109. Leung N, Cardones AR, Larrier N. Long-term improvement of recalcitrant Darier disease with photon and electron beam radiation therapy. JAAD Case Rep. 2018;4(10):1062-1064. doi:10.1016/j.jcder.2018.08.017

110. Podgorini A, Ciammella P, Ramundo D, Iotti C. Efficacy of the radiotherapy on Darier’s disease: an indirect evidence. Case Rep Dermatol Med. 2013;2013:907802. doi:10.1155/2013/907802

111. Mac Manus MP, Cavalleri G, Ball DL, Beasley M, Rotstein H, McKay MJ. Exacerbation, then clearance, of mutation-proven Darier’s disease of the skin after radiotherapy for bronchial carcinoma: a case of radiation-induced epidermal differentiation? Radiat Res. 2001;156(6):724-730. doi:10.1667/0033-7587(2001)156[724:etcomp]2.0.co;2

112. Chopra S, Sharma V, Nischal KC, Khopkar U, Baisane C, Amare KP. Darier’s disease following radiotherapy for carcinoma of cervix. Indian J Dermatol Venereol Leprol. 2004;70(5):300-303.

113. Exadaktylou D, Kurwa HA, Calonje E, Barlow RJ. Treatment of Darier’s disease with photodynamic therapy. Br J Dermatol. 2003;149(3):606-610. doi:10.1046/j.1365-2133.2003.05494.x

114. van’t Westeinde SC, Sanders CJ, van Weelden H. Variable response to low-dose naltrexone in patients with Darier’s disease: a case series. J Eur Acad Dermatol Venereol. 2019;33(5):950-953. doi:10.1111/jdv.15457